Robert Steiner, MD, professor, Division of Genetics and Metabolism, will be on a subaward to Circumvent Pharmaceuticals, Incorporated for a project titled, “Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease,” awarded by the National Institute of Neurological Disorders and Stroke. The full grant amount awarded is $2,464,063, and the specific aims of the UW subaward project are to evaluate the metabolism of NtBuHA to provide data for predicting human safety, toxicity, and Pharmacokinetics (PK); to complete all in-vivo genotoxicity studies that will be required for regulatory submissions; and to complete all remaining in-vivo toxicology and toxicokinetic (TK) studies that will be required for regulatory submissions. The funding for this grant began in August 2025 and ends in June 2027.